Taysha Gene Therapies (NASDAQ:TSHA) PT Raised to $7.00

Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its target price boosted by Cantor Fitzgerald from $6.00 to $7.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has an overweight rating on the stock. Several other research firms also recently issued reports on TSHA. Needham & Company LLC […]

Related Keywords

Switzerland ,Swiss ,Kamran Alam ,Robertw Baird ,Taysha Gene Therapies Inc ,Vanguard Group Inc ,Renaissance Technologies ,Jpmorgan Chase Co ,Cantor Fitzgerald ,Securities Exchange Commission ,Canaccord Genuity Group ,Needham Company ,Swiss National Bank ,Taysha Gene Therapies ,Free Report ,Genuity Group ,Truist Financial ,Moderate Buy ,Gene Therapies ,Exchange Commission ,Taysha Gene ,National Bank ,Get Free Report ,Taysha Gene Therapies Daily ,Nasdaq Tsha ,Ntsha ,Medical ,Boost Price Target ,